Solve your protein manufacturing problem
Developing a commercially scalable process to manufacture your recombinant protein is rife with technical challenges that can create costs, delays and quality issues – especially if your team lacks specialist skills and technology.
Phenotypeca’s expertise in strain breeding powered by QTL technology gives us the dexterity to optimise a strain proprietary to you, solving the problems that conventional methods can’t address.
Create the custom protein you need
Perhaps you’ve identified a significant commercial opportunity for a recombinant protein – but it would need specific characteristics to dominate the market. The protein might also be technically hard to create and manufacture, requiring specialist skills you don’t have access to.
Phenotypeca’s optimisation approach powered by QTL technology answers these needs by creating a commercially scalable means of manufacturing proteins – something standard methods can’t achieve.
License biosimilars
Phenotypeca is evaluating the entire formulary of recombinant protein therapeutics to harvest opportunities for the creation of premium biosimilars. Those with substantial commercial promise are being created, optimised, patent protected, and added to our pipeline.
If you don’t license a premium biosimilar with patent protection and the characteristics for market-leading differentiation – your competitor might.
